JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.00304-08v1
82/15/7721    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Lamirande, E. W.
Right arrow Articles by Subbarao, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamirande, E. W.
Right arrow Articles by Subbarao, K.

 Previous Article  |  Next Article 

Journal of Virology, August 2008, p. 7721-7724, Vol. 82, No. 15
0022-538X/08/$08.00+0     doi:10.1128/JVI.00304-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian Hamsters{triangledown}

Elaine W. Lamirande,1 Marta L. DeDiego,2 Anjeanette Roberts,1 Jadon P. Jackson,1 Enrique Alvarez,2 Tim Sheahan,3 Wun-Ju Shieh,4 Sherif R. Zaki,4 Ralph Baric,3 Luis Enjuanes,2 and Kanta Subbarao1*

Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892,1 Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB), Nacional de Biotecnología (CSIC), Campus Universidad Autónoma, Darwin 3, Cantoblanco, 28049 Madrid, Spain,2 Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599,3 Infectious Diseases Pathology Activity, Centers for Disease Control and Prevention, Atlanta, Georgia 303334

Received 11 February 2008/ Accepted 29 April 2008

The immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe acute respiratory syndrome (SARS) coronavirus lacking the E gene (rSARS-CoV-{Delta}E) were studied using hamsters. Hamsters immunized with rSARS-CoV-{Delta}E developed high serum-neutralizing antibody titers and were protected from replication of homologous (SARS-CoV Urbani) and heterologous (GD03) SARS-CoV in the upper and lower respiratory tract. rSARS-CoV-{Delta}E-immunized hamsters remained active following wild-type virus challenge, while mock-immunized hamsters displayed decreased activity. Despite being attenuated in replication in the respiratory tract, rSARS-CoV-{Delta}E is an immunogenic and efficacious vaccine in hamsters.

* Corresponding author. Mailing address: Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892. Phone: (301) 451-3839. Fax: (301) 480-5719. E-mail: ksubbarao{at}niaid.nih.gov

{triangledown} Published ahead of print on 7 May 2008.

Journal of Virology, August 2008, p. 7721-7724, Vol. 82, No. 15
0022-538X/08/$08.00+0     doi:10.1128/JVI.00304-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.